[HTML][HTML] A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib
Y Qi, J Li, S Lin, S Wu, K Chai, X Jiang, J Qian… - Scientific Reports, 2024 - nature.com
Capmatinib is a potent selective mesenchymal-epithelial transition inhibitor approved in
2020 for the treatment of metastatic non-small cell lung cancer. As real-world evidence is …
2020 for the treatment of metastatic non-small cell lung cancer. As real-world evidence is …
A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib
Y Qi, J Li, S Lin, S Wu, K Chai, X Jiang… - Scientific …, 2024 - pubmed.ncbi.nlm.nih.gov
Capmatinib is a potent selective mesenchymal-epithelial transition inhibitor approved in
2020 for the treatment of metastatic non-small cell lung cancer. As real-world evidence is …
2020 for the treatment of metastatic non-small cell lung cancer. As real-world evidence is …
[HTML][HTML] A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib
Y Qi, J Li, S Lin, S Wu, K Chai, X Jiang, J Qian… - Scientific …, 2024 - ncbi.nlm.nih.gov
Capmatinib is a potent selective mesenchymal-epithelial transition inhibitor approved in
2020 for the treatment of metastatic non-small cell lung cancer. As real-world evidence is …
2020 for the treatment of metastatic non-small cell lung cancer. As real-world evidence is …
A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib.
Y Qi, J Li, S Lin, S Wu, K Chai, X Jiang, J Qian… - Scientific …, 2024 - europepmc.org
Capmatinib is a potent selective mesenchymal-epithelial transition inhibitor approved in
2020 for the treatment of metastatic non-small cell lung cancer. As real-world evidence is …
2020 for the treatment of metastatic non-small cell lung cancer. As real-world evidence is …
A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib
Y Qi, J Li, S Lin, S Wu, K Chai, X Jiang… - Scientific …, 2024 - ui.adsabs.harvard.edu
Capmatinib is a potent selective mesenchymal-epithelial transition inhibitor approved in
2020 for the treatment of metastatic non-small cell lung cancer. As real-world evidence is …
2020 for the treatment of metastatic non-small cell lung cancer. As real-world evidence is …
A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib.
Y Qi, J Li, S Lin, S Wu, K Chai, X Jiang… - Scientific …, 2024 - search.ebscohost.com
Capmatinib is a potent selective mesenchymal-epithelial transition inhibitor approved in
2020 for the treatment of metastatic non-small cell lung cancer. As real-world evidence is …
2020 for the treatment of metastatic non-small cell lung cancer. As real-world evidence is …